The Food and Drug Administration said on Monday that it will not enforce a restriction that requires abortifacients to be obtained in person.
The requirement was implemented as part of the Risk Evaluation and Mitigation Strategies meant to protect from harmful reactions and health concerns such as hemorrhage that may occur with the use of such chemicals.
Acting Commissioner of Food and Drugs Dr. Janet Woodcock said an evaluation of the abortion pill mifepristone – which starves an unborn child developing in the womb – showed no major "increases in serious safety concerns."
The agency will allow women to obtain the pill "through the mail either by or under the supervision of a certified prescriber, or through a mail-order pharmacy when such dispensing is done under the supervision of a certified prescriber."
Marjorie Dannenfelser, president of the pro-life advocacy group Susan B. Anthony List, said the move "prioritizes abortion industry profits over the health and safety of women" and shows how abortion activists "have exploited the COVID-19 pandemic."
Carol Tobias, president of National Right to Life, echoed those sentiments.
"Abortion groups now argue that, during the pandemic, it is ‘safer' not to evaluate and monitor a woman taking abortion drugs than to have her come to the office," she said. "An office visit would confirm that she is not too far along for the pills to work or that she does not have an ectopic pregnancy, which these pills do not treat and can prove deadly to a woman if it goes undetected."